Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib
Sign Up to like & getrecommendations! Published in 2019 at "Targeted Oncology"
DOI: 10.1007/s11523-019-00657-1
Abstract: The first (1G) and second (2G) generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) show differential inhibitory capacities towards EGFR T790M-mutated non-small-cell lung cancer (NSCLC) cells. To assess the ratio of the… read more here.
Keywords: egfr mutated; egfr; acquired t790m; efficacy osimertinib ... See more keywords
Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2018.11.037
Abstract: Objectives The efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR T790 M resistance mutation was demonstrated in clinical trials. However, data on efficacy of osimertinib in real world remain… read more here.
Keywords: pretreated patients; efficacy osimertinib; mutation; lung cancer ... See more keywords
Different efficacy of osimertinib in pre-TKI treated NSCLC patients with brain metastases harboring EGFR exon 19del and L858R mutant.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e21667
Abstract: e21667Background: Previous studies suggested that the efficacy of osimertinib was better in patients with epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) than exon 21 Leu858Arg (... read more here.
Keywords: egfr exon; osimertinib pre; different efficacy; efficacy osimertinib ... See more keywords